Gilead Sciences
Gilead’s Breakthrough CAR-T Becomes First to Get FDA Approval for Indolent Follicular Lymphoma
2021-03-07
Gilead Aspires to Prolong Leadership in HIV Market, Launches Therapeutic Vaccine Quest with Gritstone
2021-02-03
Gilead and Novo Nordisk Present Proof-of-Concept Data for the First Possible NASH Treatment
2020-11-17
First to the Finish Line! Remdesivir Becomes the First and Only FDA Approved Drug to Treat COVID-19
2020-10-23
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115